New combo therapy aims to stop breast cancer return

NCT ID NCT05996107

Recruiting now Disease control Sponsor: University of Michigan Rogel Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This early-phase study is testing whether the drug ribociclib (Kisqali) can be safely given alongside standard radiation therapy after surgery for women with a high-risk type of breast cancer (HR+/HER2-). About 30 participants will take ribociclib daily for up to 6 weeks while receiving radiation. The main goal is to find the safest dose and watch for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ribociclib (Kisqali) plus radiation therapy
What this could lead to: If successful, this could show that adding ribociclib to standard radiation is safe and may help prevent breast cancer from coming back in high-risk patients.
What could go wrong: This is a very early phase 1 trial with only 30 people, so it is mainly checking safety and the right dose. It is too small to prove if the combination actually works better than radiation alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

UHCMC Seidman Cancer Center
RECRUITING

Cleveland, Ohio, 44106, United States
University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109, United States
University of Michigan Health West
RECRUITING

Wyoming, Michigan, 49519, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.